Thiazide add-ons linked to lower risks in non-dialysis kidney disease
For heart and blood vessel events, calcium channel blockers had an adjusted hazard ratio (relative risk over time) of 1.18 compared with thiazide diuretics.

Our read
Interventions- Studied:
- Cohort study of 150,369 adults with non-dialysis chronic kidney disease, median 1,282 days
- What changed:
- Heart and blood vessel event risk was higher with calcium channel blockers than thiazides (adjusted hazard ratio 1.18)
- The catch:
- Advanced kidney disease and heart failure were more common with loop diuretics, potentially confounding comparisons
- In the record:
- The 74th paper on beta-blockers with results in people; 304 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
Adults with chronic kidney disease who were not receiving dialysis were studied in a target trial emulation, an analysis designed to mimic a clinical trial using existing records. The 150,369 adults were already taking an ACE inhibitor or angiotensin receptor blocker, two standard types of blood pressure drug. They added a second drug in Veterans Health Administration records from 2010 through 2016.
Over a median 1,282 days, thiazide diuretics—drugs that help the body remove salt and water—were linked to more favorable heart and kidney outcomes. Compared with thiazides, adjusted hazard ratios for heart and blood vessel events were 1.18 for calcium channel blockers, 1.63 for beta-blockers and 1.97 for loop diuretics. All three were also linked to higher risks of the combined kidney outcome, which included starting dialysis or receiving a kidney transplant.
Why it matters
For chronic kidney disease care, the findings may help inform the choice of a second blood pressure drug—a choice current guidelines do not specify.
Caveats
People prescribed loop diuretics more often had advanced kidney disease or heart failure, so differences in health may have contributed to the outcome differences. The findings do not cover people already receiving dialysis.
The paper
Association of Second Anti-hypertensive Agent with Outcomes in People with CKD on ACEi/ARB Therapy
Michael E. DeBakey VA Medical Center; VA North Texas Health Care System
Journal of the American Society of Nephrology, Nov 13, 2026


Comments
Be the first to comment.